about
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSilencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions.Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways.Berberine attenuates myocardial ischemia reperfusion injury by suppressing the activation of PI3K/AKT signalingIdelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Gelsolin regulates proliferation, apoptosis and invasion in NK/T-cell lymphoma cells.MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.Inhibition of Ras-mediated signaling pathways in CML stem cells.PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Phosphorylation-Dependent Inhibition of Akt1
P2860
Q26991637-E3B67A92-BFD1-46AF-A76A-45CEC988C084Q28075606-985287AF-D82E-4E78-8BF9-1E732E5D8E81Q28817964-95AA4E65-4BBA-4474-A25B-A2A35F004238Q30275870-4F63EAEC-1409-4399-866F-4F1D1F6ED0A2Q33429430-68DBAC54-C950-4771-9F57-8E3EF19E3664Q33919290-F547D104-8CA8-4E42-8090-B8A0ED7DAF9AQ36480193-6A78694D-A05D-4872-9494-40ED60EF3B35Q36524163-FC1CDE9F-529F-4896-8EBE-B83BAC7A7F8EQ36639943-2707ED07-DE06-4228-A599-5E7AD4D22AE6Q38581826-60892A05-98A6-408E-B074-8C94D9A33FCDQ38830812-FF72626F-5DE9-40BD-8207-72CCC951B6C2Q39171305-4AC79D64-93A2-48A4-8E4D-97FE8686C28DQ41057184-3C62A135-FEF7-4AEC-B4AE-05980F076185Q41994564-5A5D6DE3-CE11-4788-A8EC-6ABD11344CF3Q47364413-E43E91AD-C0DB-4190-82B7-517A6DB403FFQ49547726-35BF1906-D0C5-4F5C-B20B-F5F7E9F9A389Q52566933-1DF1B3DE-F3F2-4AA5-9899-04C537C58B19Q52658477-B722CE53-5599-42C9-89B4-0010B25AA419Q53314331-6D9479B7-B3AE-4DEA-9825-82D1C0E7DC61Q54151779-65D708EC-B239-4DE0-B382-E0B1AC2398BFQ54982413-869F4DF9-65E9-4F7C-8A65-B130AFF23881Q55139939-8D64D435-2023-4EE3-B0E7-B47ED7B3B289Q55281964-F07666A2-AE55-4799-8624-FF77D3CCB5FAQ58758462-754A2035-2CEC-49A1-B799-860E70C0C8B5
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@ast
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@en
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@nl
type
label
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@ast
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@en
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@nl
prefLabel
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@ast
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@en
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@nl
P2860
P3181
P1476
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
@en
P2093
Jason R. Westin
P2860
P304
P3181
P356
10.1016/J.CLML.2014.01.007
P407
P577
2014-10-01T00:00:00Z